Studies Selected for Presentation at Global Gathering FORT MYERS, Fla. , Nov. 7, 2024 /PRNewswire/ -- Clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) continues to advance science and breakthroughs in cancer immunotherapy, which uses the body's immune system to find, target and fight many forms of the disease.
FCS physician investigators are co-authors of research results being presented this week at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston , the largest cancer immunotherapy conference of international leaders in the field. FCS President & Managing Physician Lucio N. Gordan , MD said, "Our shared aim is to make immunotherapy a standard of care to improve outcomes for cancer patients.
Each discovery achieved through our robust clinical trials research program is bringing us closer to that reality." The following FCS physician investigators are co-authors of research results being presented during oral and/or poster abstract presentations: FCS Director of Drug Development Manish Patel , MD : Phase 1B /2, multicenter dose escalation and expansion of muzstotug (ADG126, a masked anti-CTLA-4 SAFEbody ® ) in combination with Pembrolizumab in advanced/metastatic MSS CRC (abstract #744); Noted as a "Top 100" Evaluation of immunomodulatory effects of ifinatamab deruxtecan (I-DXd) in the IDeate-Pantumor01 phase 1/2 study in patients with advanced solid tumors (abstract #629) A phase 1/2 clinic.
